For patients with ER+/HER2- advanced breast cancer, current treatment guidelines recommend the use of endocrine therapy plus a CDK 4/6 inhibitor as a first-line treatment. And while the guidelines recommend sequential endocrine therapy for disease progressions, this progression can lead to ESR1 mutations and resistance to endocrine therapy. Could a novel oral selective estrogen receptor have more efficacy in preventing ESR1 mutations associated with endocrine resistance? That’s the exact question the EMERALD trial sought to answer, and what this study found in its subgroup analyses is the focus of this Audio Abstract.

Results from a recent study detail the impact that fungi can have in human cancer tumors. What do we need to know? Mario Nacinovich speaks with one of the researchers, Dr. Gregory Sepich-Poore from UC San Diego, to dive further into these results and their impact on cancer therapeutics.

Endocrine resistance and toxicities are just a few of the many challenges facing clinicians who treat patients with ER+/HER2- advanced breast cancer. So what strategies can we use to better address these challenges and unmet needs? Joining Dr. Jennifer Caudle to share her approach is Dr. Stephanie Graff, Director of the Breast Oncology Program at Lifespan Cancer Institute in Providence, Rhode Island.

Selective estrogen receptor degraders (SERDs) are a novel class of drugs for the treatment of ER+/HER2- advanced breast cancer. So how exactly do they work to treat this type of advanced breast cancer, and what are the findings from recent trials investigating the clinical utility of SERDs? Get the answers to these and other key questions with Dr. Jennifer Caudle and Dr. Nan Chen, Assistant Professor of Medicine at the University of Chicago School of Medicine.

Endocrine therapy is the recommended treatment for ER+/HER2- advanced breast cancer, but progression to advanced disease can lead to ESR1 mutations, which can then lead to endocrine therapy resistance. But could treatment with an oral selective estrogen receptor degrader (SERD) improve outcomes for our patients? Join us as we take a deep dive into the EMERALD trial, which explored that exact question, in this Audio Abstract.

What do we need to know about the therapeutic landscape and management of myelofibrosis-related anemia? Here to share their perspectives with Dr. Charles Turk are Dr. Raajit Rampal from the Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai.

Given the challenges and unmet needs associated with the current treatment options for ER+/HER2- advanced breast cancer, what strategies can we use to optimize our approach? Here with Dr. Jennifer Caudle to share their perspectives are Dr. Stephania Graff from Lifespan Cancer Institute and Dr. Pavani Chalasani from the University of Arizona Cancer Center.

Can multi-cancer early detection (MCED) tests potentially lead to a reduction in the number of people who die from the disease by improving screening rates and extending screening for cancers without standard screening today? So what do we need to know about these tests? To discuss this more in-depth, Dr. Charles Turck is joined by Dr. Tomasz Beer, Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation and Adjunct Professor of Medicine at the OHSU Knight Cancer Institute.

© 2022 Exact Sciences Corporation. All rights reserved.
US.CAG.00020.HCP 12/22

Listen in as Wui-Jin Koh, MD, Senior Vice President and Chief Medical Officer of the National Comprehensive Cancer Network, highlights the need for this important, new digital curriculum designed to support your care of patients across multiple solid tumor types.

There are two key unmet needs in the treatment of myelofibrosis. Here to share what those are and how we can work to address them is Dr. Aaron Gerds from the Cleveland Clinic.